Loading the content... Loading depends on your connection speed!

Shopping Cart - $0.00

Skin Cancer Market Global Briefing 2017

Skin Cancer Market Global Briefing 2017

From $1,000.00

Including: Drugs For – Merkel Cell Carcinoma, Actinic Keratoses, Basal Cell Carcinoma, Squamous Cell Carcinoma, And Melanoma.
Covering: Amgen, Eisai, Bristol-Myers Squibb, F. Hoffmann-La Roche


Clear selection
SKU: 2263. Category: .
Description

Skin cancer Market Global Briefing 2017 from The Business Research Company provides the strategists, marketers and senior management with the critical information they need to assess the global skin cancer market.

Description

The Skin cancer Market Global Briefing Report from The Business Research Company covers market characteristics, size and growth, segmentation, regional breakdowns, competitive landscape, market shares, trends and strategies for this market.

The skin cancer market is one of the segments in the oncology drugs market, within the pharmaceutical drugs market.

The market characteristics section of the report defines and explains the market.

The market size section gives the skin cancer market revenues, covering both the historic growth of the market and forecasting the future.

Drivers and restraints looks at the external factors supporting and controlling the growth of the market.

Market segmentations break down the key sub sectors which make up the market. The regional breakdowns section gives the size of the market geographically.

Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in the last three years are identified.

The trends and strategies section highlights the likely future developments in the skin cancer market and suggests approaches.

Reasons to Purchase

• Get up to date information available on the skin cancer market globally.
• Identify growth segments and opportunities.
• Facilitate decision making on the basis of historic and forecast data and understand the drivers and restraints on the market.
• Develop strategies based on likely future developments.
• Gain a global perspective on the development of the market.
• Report will be updated with the latest data and delivered to you within 2-3 working days of order.

Scope

Markets Covered: Drugs For – Merkel Cell Carcinoma, Actinic Keratoses, Basal Cell Carcinoma, Squamous Cell Carcinoma, And Melanoma.

Companies Mentioned: Amgen, Eisai, Bristol-Myers Squibb, F. Hoffmann-La Roche.

Countries: Brazil, China, France, Germany, India, Italy, Japan, Spain, Russia, UK, USA and Australia.

Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East And Africa

Time series: Five years historic and forecast.

Data: Market value in $ billions.

Data segmentations: Regional breakdowns, market share of competitors, key sub segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Related Reports:
Lung cancer Market Global Briefing 2017
Pancreatic cancer Market Global Briefing 2017
Breast cancer Market Global Briefing 2017
Prostate cancer Market Global Briefing 2017
Ovarian cancer Market Global Briefing 2017
Gastric Cancer Market Global Briefing 2017
Non-Small Cell Lung Cancer Market Global Briefing 2017
Brain Tumor Market Global Briefing 2017
Colorectal Cancer Market Global Briefing 2017
Thyroid cancer Market Global Briefing 2017
Bladder Cancer Market Global Briefing 2017
Kidney Cancer Market Global Briefing 2017
Cervical Cancer Market Global Briefing 2017
Blood cancer Market Global Briefing 2017

Table Of Contents
Table Of Contents

1. Introduction
2. Skin cancer Market Characteristics
3. Skin cancer Market Historic Growth
• Drivers Of The Market
• Restraints On The Market
4. Skin cancer Market Forecast Growth
• Drivers Of The Market
• Restraints On The Market
5. Skin cancer Market Geography Split
6. Skin cancer Market As A Proportion of Oncology Drugs Market, 2016, By Region
7. Skin cancer Market As A Proportion of Oncology Drugs Market, 2016, By Country
8. Skin cancer Market Segmentation
9. Skin cancer Competitive Landscape
Amgen
Eisai
Bristol-Myers Squibb
F. Hoffmann-La Roche
10. Key Mergers And Acquisitions In The Skin cancer Market
11. Skin cancer Market Trends And Strategies
Appendix
NAICS Definitions of Industry Covered In This Report
Research Methodology
Methodology
Data
Market Numbers
Competitor Market Share Data
Analysis
Verification Through Expert Interviews
Referencing
Note on Currency Conversions
Abbreviations
Currencies
Research Inquiries
The Business Research Company

List Of Tables
Table 1: Global Skin cancer Market Historic Market Size, 2012 – 2016, $ Billion
Table 2: Global Skin cancer Market Forecast Market Size, 2016 – 2020, $ Billion
Table 3: Global Skin cancer Market, Split By Region, 2016, $ Billion
Table 4: Skin cancer Market As A Proportion of Oncology Drugs Market, 2016, By Region
Table 5: Skin cancer Market As A Proportion of Oncology Drugs Market, 2016, By Country
Table 6: Global Skin cancer Market, Key Competitor Shares, 2016, Percentage (%)
Table 7: Global Skin cancer Market, Split By Segments, 2016, $ Billion

List Of Figures
Figure 1: Global Skin cancer Market Historic Market Size, 2012 – 2016, $ Billion
Figure 2: Global Skin cancer Market Forecast Market Size, 2016 – 2020, $ Billion
Figure 3: Global Skin cancer Market, Split By Region, 2016, $ Billion
Figure 4: Skin cancer Market As A Proportion of Oncology Drugs Market, 2016, By Region
Figure 5: Skin cancer Market As A Proportion of Oncology Drugs Market, 2020, By Country
Figure 6: Global Skin cancer Market, Key Competitor Shares, 2016, Percentage (%)
Figure 7: Global Skin cancer Market, Split By Segments, 2016, $ Billion
Executive Summary
The skin cancer drugs market cover drugs that are used treat cancer that affect skin. These indications include Merkel Cell Carcinoma, Actinic Keratoses, Basal cell carcinoma, Squamous cell carcinoma, and Melanoma. Some of the major drugs in this market are Zelboraf (Vemurafenib), Yervoy (Ipilimumab), Vemurafenib, Trametinib, Talimogene Laherparepvec, Tafinlar (Dabrafenib), Sylatron (Peginterferon Alfa-2b), Recombinant Interferon Alfa-2b, Proleukin (Aldesleukin), Pembrolizumab, Peginterferon Alfa-2b, Opdivo (Nivolumab), Nivolumab, Mekinist (Trametinib), Keytruda (Pembrolizumab), Ipilimumab, Intron A (Recombinant Interferon Alfa-2b), Interleukin-2 (Aldesleukin), Imlygic (Talimogene Laherparepvec), IL-2 (Aldesleukin), DTIC-Dome (Dacarbazine), Dacarbazine, Dabrafenib, Cotellic (Cobimetinib), Cobimetinib, and Aldesleukin.

The global skin cancer market was estimated to be around $1.2 billion as of 2016. The global skin cancer made up around 1% of the overall oncology drugs market in 2016. The skin cancer market was the twelfth largest market in the global oncology drugs market in 2016.

Acquisitions
Acquisition of skin cancer business segment or product portfolio from another competitors in this market is an emerging trend in the market. For instance, in December 2016, Sun Pharmaceutical Industries Ltd. Acquired Odomzo drug portfolio from Novartis AG for approximately $175 million. Odomzo is used treatment of advanced basal cell carcinoma that recurs after a surgery or a radiation therapy. Through this initiative Sun Pharmaceutical Industries Ltd. entered into skin cancer drugs market in the US and Europe markets.

Product Approval
Product approvals from regulatory bodies such as FDA in the US and EMA in Europe is one of the major trend in this market. For instance, in January 2016, Bristol-Myers Squibb received NHS approval for commercialization of its nivolumab in the UK market. It is used in the treatment of melanoma.
Get Customized Report
Please fill in your details. Our team will get back to you